Processa CEO buys 2,465 shares at $2.22

Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,465 shares of Common Stock at $2.22 per share.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,465 shares of Common Stock at $2.22 per share. Following this trade, his directly held Common Stock position increased to 12,435 shares.

Ng also reports indirect ownership of Common Stock, including 800 shares held through the Ng Cha Family Trust and 3,488 shares held through an account labeled George Ng IRRA FOB George Ng.

Insights

Equity compensation and insider-trading analyst

CEO George Ng made a modest open-market share purchase, adding to his direct stake.

The filing shows Processa Pharmaceuticals CEO George K. Ng executed an open-market purchase of 2,465 Common Stock shares at $2.22 per share, a discretionary buy rather than a grant or tax withholding. His directly owned holdings rose to 12,435 shares after the transaction.

The filing also lists indirect holdings of 800 shares via the Ng Cha Family Trust and 3,488 shares through another account, indicating additional exposure beyond his direct position. No derivative positions are reported in this filing, so the current equity exposure is entirely in Common Stock.

Insider Trade Summary

Net Buyer: 2,465 shares

Net Buy 3 txns

Insider Ng George K

Role Chief Executive Officer

Bought 2,465 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,465	$2.22	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 12,435 shares (Direct); Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng); Common Stock — 800 shares (Indirect, Ng Cha Family Trust)

Key Figures

Open-market purchase: 2,465 shares Purchase price: $2.22 per share Direct holdings after trade: 12,435 shares +2 more

5 metrics

Open-market purchase 2,465 shares Common Stock bought on 2026-06-15

Purchase price $2.22 per share Price for 2,465 Common Stock shares

Direct holdings after trade 12,435 shares Common Stock directly owned by CEO after purchase

Indirect holdings via Ng Cha Family Trust 800 shares Common Stock held indirectly

Indirect holdings via IRRA account 3,488 shares Common Stock held indirectly in George Ng IRRA FOB account

Key Terms

open-market purchase, indirect ownership, Common Stock

3 terms

open-market purchase financial

"reported an open-market purchase of 2,465 shares of Common Stock at $2.22"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"Ng also reports indirect ownership of Common Stock, including 800 shares held through the Ng Cha Family Trust"

Common Stock financial

"shares of Common Stock at $2.22 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Processa Pharmaceuticals (PCSA) CEO George Ng do in this Form 4?

George K. Ng, CEO of Processa Pharmaceuticals, reported an open-market purchase of 2,465 shares of Common Stock at $2.22 per share. This transaction increased his directly held Common Stock position to 12,435 shares, according to the Form 4 filing.

How many Processa Pharmaceuticals shares does CEO George Ng own directly after this trade?

After the reported open-market purchase, George K. Ng directly holds 12,435 shares of Processa Pharmaceuticals Common Stock. The filing shows this post-transaction balance as his direct ownership figure, separate from additional indirect holdings reported through related accounts.

At what price did the Processa Pharmaceuticals CEO buy PCSA shares?

The CEO’s reported open-market purchase was executed at a price of $2.22 per share. He acquired 2,465 shares of Processa Pharmaceuticals Common Stock at this price, as disclosed in the Form 4 insider trading report filed with regulators.

Does George Ng have indirect holdings of Processa Pharmaceuticals stock?

Yes. The filing lists 800 shares of Common Stock held indirectly through the Ng Cha Family Trust and 3,488 shares held indirectly through an account labeled George Ng IRRA FOB George Ng. These positions are reported as indirect ownership interests.

Is this Processa Pharmaceuticals Form 4 transaction a purchase or a sale?

The key transaction disclosed is an open-market purchase of 2,465 shares of Common Stock. The filing uses transaction code P and describes it as a purchase in the open market or a private transaction, indicating a buying action by the reporting person.

Are there any derivative securities reported for Processa Pharmaceuticals’ CEO in this filing?

No derivative securities are listed for the CEO in this Form 4. The derivativeSummary section is empty, and all reported positions relate to Common Stock, showing only direct and indirect holdings and the single open-market purchase transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		P		2,465	A	$2.22	12,435	D
Common Stock								3,488	I	George Ng IRRA FOB George Ng
Common Stock								800	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)